{"id":"NCT00755807","sponsor":"Eli Lilly and Company","briefTitle":"Duloxetine for Multiple Sclerosis Pain","officialTitle":"Duloxetine in Patients With Central Neuropathic Pain Due to Multiple Sclerosis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2010-08","completion":"2010-11","firstPosted":"2008-09-19","resultsPosted":"2011-12-09","lastUpdate":"2011-12-09"},"enrollment":239,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Duloxetine Hydrochloride (HCI)","otherNames":["LY248686","Cymbalta"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Duloxetine","type":"EXPERIMENTAL"}],"summary":"This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD) compared with placebo on the reduction of pain severity in participants with central neuropathic pain due to Multiple Sclerosis.","primaryOutcome":{"measure":"Change From Baseline in the Weekly 24-Hour Average Pain Scores at Week 6 (Acute Phase)","timeFrame":"Baseline, 6 weeks","effectByArm":[{"arm":"Duloxetine","deltaMin":-1.83,"sd":0.17},{"arm":"Placebo","deltaMin":-1.07,"sd":0.16}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":22,"countries":["United States","Belgium","Canada","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":118},"commonTop":["Fatigue","Nausea","Dizziness","Headache","Constipation"]}}